Posted innews Respiratory Specialties
Targeting IL-33 in COPD: Insights from the Phase 2a FRONTIER-4 Trial of Tozorakimab
The FRONTIER-4 phase 2a trial evaluated tozorakimab, an anti-IL-33 monoclonal antibody, in moderate-to-severe COPD with chronic bronchitis. While the primary endpoint was unmet in the overall population, efficacy signals emerged in patients with frequent exacerbations, supporting ongoing phase 3 studies.